Sensei Biotherapeutics (NASDAQ:FTH) Given Buy Rating at BTIG Research

Sensei Biotherapeutics (NASDAQ:FTH)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a note issued to investors on Tuesday, Benzinga reports. They presently have a $55.00 price objective on the stock. BTIG Research‘s price objective suggests a potential upside of 226.80% from the company’s current price.

FTH has been the subject of a number of other reports. William Blair began coverage on shares of Sensei Biotherapeutics in a report on Friday, October 16th. They issued an “outperform” rating for the company. TD Cowen assumed coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, September 9th. They set a “buy” rating on the stock. JonesTrading started coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, August 4th. They set a “buy” rating and a $55.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, September 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Stock Performance

Shares of Sensei Biotherapeutics stock opened at $16.83 on Tuesday. The company’s 50 day moving average price is $29.91. Sensei Biotherapeutics has a 12 month low of $7.45 and a 12 month high of $42.14. The company has a market capitalization of $434.89 million, a price-to-earnings ratio of -0.12 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. On average, sell-side analysts predict that Sensei Biotherapeutics will post -13.69 earnings per share for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several institutional investors have recently modified their holdings of FTH. Citadel Advisors LLC bought a new position in shares of Sensei Biotherapeutics during the 2nd quarter valued at approximately $307,000. Alyeska Investment Group L.P. bought a new stake in Sensei Biotherapeutics in the second quarter worth $3,610,000. Vivo Capital LLC bought a new stake in Sensei Biotherapeutics in the first quarter worth $22,758,000. Bank of America Corp DE boosted its stake in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the period. Finally, Stempoint Capital LP purchased a new position in Sensei Biotherapeutics during the first quarter worth $4,188,000. 10.50% of the stock is owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.